Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Commentary: Comparison of activated charcoal and sodium polystyrene sulfonate resin efficiency on reduction of amitriptyline oral absorption in rat as treatments for overdose and toxicities457457866610.22038/ijbms.2017.8666ENYoustina MichaelDepartment of Emergency Medicine, Coney Island HospitalLaura PWeberNew York University School of MedicineMorgan RigganDivision of Medical Toxicology, Ronald O Perelman Department of Emergency Medicine, New York University School of MedicineRobert SHoffmanDivision of Medical Toxicology, Ronald O Perelman Department of Emergency Medicine, New York University School of MedicineJournal Article20170502Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Construction, expression, purification and characterization of secretin domain of PilQ and triple PilA-related disulfide loop peptides fusion protein from Pseudomonas aeruginosa458466866710.22038/ijbms.2017.8667ENSobhan FaeziDepartments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, IranMicrobiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran0000-0002-4611-9985Ahmad Reza BahrmandDepartments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, IranMicrobiology Research Center (MRC), Pasteur Institute of Iran, Tehran, IranSeyed Davar SiadatDepartments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, IranMicrobiology Research Center (MRC), Pasteur Institute of Iran, Tehran, IranIraj NikokarDepartment of Biotechnology, Laboratory of Microbiology and Immunology of Infectious Diseases, Para Medicine Faculty, Guilan University of Medical Sciences, Rasht, IranSoroush SardariBiotechnology Research Center, Drug Design and Bioinformatics Group, Pasteur Institute of Iran, Tehran, IranMehdi MahdaviDepartments of Immunology, Pasteur Institute of Iran, Tehran, Iran0000-0003-4478-5957Journal Article20170502<strong><em>Objective(s)</em></strong>: Infection with <em>Pseudomonas aeruginosa</em> has been a long-standing obstacle for clinical therapy due to the complexity of the genetics and pathogenesis, as well for widespread resistance to antibiotics, thus attaching great importance to explore effective vaccines for prevention and treatment. This paper focuses on the introduction of novel <em>Pseudomonas aeruginosa</em> type IV pili (T4P)-based fusion protein containing the secretin domain of PilQ and tandem PilA-related peptides.<br /> <strong><em>Materials and Methods: </em></strong>We surveyed the expression of the PilQ<sub>380-705</sub><em>-</em>PilA fusion protein in-frame with pET26b vector in which a rigid linker was used between two polypeptides and flexible linkers were inserted between the three tandem repeats and each <em>pilA</em> domain<strong>s</strong>. The transformants were expressed in <em>Escherichia coli</em> BL21. The reactivity of specific antisera to the fusion protein was assessed by ELISA. The biological activities of this candidate vaccine were evaluated by western blotting, opsonophagocytosis, and twitching inhibition assays.<br /> <strong><em>Results:</em></strong> The fusion protein was purified in high yield by osmotic shock method using HisTrap affinity column. The protein was confirmed by immunoblot analysis. The checkerboard titration showed that the optimal dilution of the antibody to react with antigen is 1:128. Results of opsonophagocytosis assay revealed that the antibodies elevated to the fusion protein promoted phagocytosis of the PAO1 and 6266E strains, so that the twitching immobilization test confirmed these results.<br /> <strong><em>Conclusion:</em></strong> Due to excellent killing activity mediated by opsonic antibodies and efficient immobilization of the strains, it seems that PilQ<sub>380-705</sub>-PilA fusion protein could be a reliable candidate vaccine against <em>P. aeruginosa</em> infection.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501One-step purification and characterization of alginate lyase from a clinical Pseudomonas aeruginosa with destructive activity on bacterial biofilm467473866810.22038/ijbms.2017.8668ENParinaz GhadamDepartment of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran0000-0001-7808-6973Fatemeh AkhlaghiDepartment of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, IranAhya Abdi AliDepartment of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, IranJournal Article20170502<strong><em>Objective(s)</em></strong>: <em>Pseudomonas aeruginosa</em>is a Gram-negative and aerobic rod bacterium that displays mucoid and non-mucoid phenotype. Mucoid strains secrete alginate, which is the main agent of biofilms in chronic <em>P. aeruginosa</em> infections, show high resistance to antibiotics; consequently, the biological disruption of mucoid <em>P. aeruginosa</em> biofilms is an attractive area of study for researchers. Alginate lyase gene <em>(algl)</em> is a member of alginate producing operon which by glycosidase activity produces primer for other enzymes in this cluster. Also this activity can destroy the extracellular alginate; therefore this enzyme participates in alginate production and destruction pathway. Alginate lyase causes detachment of a biofilm by reducing its adhesion to the surfaces, and increases phagocytosis and antibiotic susceptibility. In this study, alginate lyase was purified in just one step and its properties were investigated.<br /> <strong><em>Materials and Methods: </em></strong>The purification was done by affinity chromatography, analysed by SDS-PAGE, and its effect on <em>P. aeruginosa</em> biofilms was surveyed by micro titer plate assay and SEM. The substrate specificity of the enzyme was determined by PCR.<br /> <strong><em>Results:</em></strong> Alginate lyase from isolate 48 was purified in one step. It is more thermally resistant than alginate lyase from<em> Pseudomonas aeruginosa</em> PAO1 and poly M, poly G and poly MG alginate were the substrate of this enzyme. Moreover, it has an eradication effect on biofilms from <em>P. aeruginosa</em> 48 and PAO1.<br /> <strong><em>Conclusion:</em></strong> In this study an alginate lyase with many characteristics suitable in medicine such as thermal stability, effective on poly M alginate, and bacterial biofilm destructive was introduced and purified.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer’s disease474480866910.22038/ijbms.2017.8669ENLi WangDepartment of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, ChinaWei LiuDepartment of Neurology, Peking University Third Hospital, Beijing 100080, ChinaYing FanDepartment of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, ChinaTingting LiuDepartment of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, ChinaChunjiang YuDepartment of Neurology, The Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, ChinaJournal Article20170502<strong><em>Objective(s)</em></strong>: Increasing evidence suggests that Alzheimer’s disease (AD) is associated with diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD. However, the underlying therapeutic potential of it has not been fully elucidated.<br /> <strong><em>Materials and Methods: </em></strong>Rats were divided into four groups: control group, sham operated group, Streptozotocin (STZ) group, rosiglitazone (RGZ) group. Particularly, the STZ-induced rat model was established by intracerebroventricular injection (3 mg/kg) on the first and third day. The water maze behavioral test was performed to evaluate spatial reference learning and memory of the rats. Aβ1-40 and Aβ1-42 levels were measured by ELISA method. To determine APP-derived fragment, BACE1 and Aβ degrading enzymes levels, such as NEP and IDE, as well as Aβ transportation protein level, such as LRP1, RAGE, Abca1 and APOE , which were analyzed by Western blot. Immunohistochemistry was used to observe the change of Aβ1-40 and Aβ1-42 in hippocampus.<br /> <strong><em>Results:</em></strong> Chronic treatment with RGZ could reduce the Aβ level and improved spatial memory performance in STZ-induced rat model. However, RGZ modified the expression of specific transport proteins monitoring Aβ clearance, such as ATP-binding cassette transporter 1 (ABCA1), lipoprotein receptor-related protein 1 (LRP1), and the advanced glycation end product-specific receptor (RAGE) rather than change levels of Aβ degrading enzymes, such as IDE and NEP, nor affect APP processing. <br /> <strong><em>Conclusion:</em></strong> As a potential therapeutic strategy, rosiglitazone might exert anti-AD effect not by alteration of APP processing pathway and Aβ degradation directly, but through promotion of Aβ clearance indeed.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501MiR-570 inhibits cell proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous leukemia481488867110.22038/ijbms.2017.8671ENHong ZhaoDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaFei LiuDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaRuichun JiaDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaHuiying ChangDepartment of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaHaixia LiDepartment of Ultrasonography, Harbin medical university cancer hospital, Harbin, Heilongjiang 150081, ChinaMeijuan MiaoDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaHui WangDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaZhiping YangDepartment of Blood Transfusion, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, ChinaJournal Article20170502<strong><em>Objective(s)</em></strong>: Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder characterized by the accumulation of myeloid cells with a chromosomal translocation known as the Philadelphia chromosome. In this study, we investigated the roles of miR-570 in CML development.<br /> <strong><em>Materials and Methods: </em></strong>Expression of miR-570 in CML samples and cell lines was determined by qRT-PCR. Glucose uptake and ATP concentration detection assays were used to analyze cell glucose metabolism. MTT and western blot assays were performed for cell proliferation and apoptosis, respectively. The targets of miR-570 were predicted by bioinformatics and confirmed using luciferase activity, qRT-PCR and western blot assays.<br /> <strong><em>Results:</em></strong> The expression levels of miR-570 were significantly reduced in CML clinical samples and cells. Overexpression of miR-570 inhibited cell proliferation, promoted apoptosis, and suppressed glucose metabolism in CML cells. Insulin receptor substrates (IRS) 1 and IRS2 were identified as direct targets of miR-570. IRS1 or IRS2 were knocked down in K562 cells.Loss of IRS1/2 expression led to suppressed cell proliferation, elevated apoptosis, and decreased glucose metabolism in CML cells, which is consistent with their roles as miR-570 targets.<br /> <strong><em>Conclusion:</em></strong> MiR-570 directly targeted IRS1 and IRS2 in CML, suppressing cell proliferation and glucose metabolism. MiR-570 may provide a strategy for CML therapy.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies489496867210.22038/ijbms.2017.8672ENVFatemeh Kazemi-Lomedasht VBiotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, IranKamran Pooshang-BagheriBiotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, IranMahdi Habibi-AnbouhiNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, IranEnsiyeh Hajizadeh-SafarNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, IranDelavar ShahbazzadehBiotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran0000-0002-9066-8666Hasan MirzahosseiniBiotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, IranMahdi BehdaniBiotechnology Research Center, Biotechnology Department, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran0000-0002-4839-5123Journal Article20170502<strong><em>Objective(s)</em></strong>: Lung cancer is the main leading cause of cancer death worldwide. Angiogenesis is the main step in proliferation and spreading of tumor cells. Targeting vascular endothelial growth factor (VEGF) is an effective approach for inhibition of cancer angiogenesis. Nanobodies (NBs) are a novel class of antibodies derived from the camel. Unique characteristics of Nbs like their small size and good penetration to tumor tissues makes them promising tools in drug development. Development of NBs targeting both human and mouse VEGF is required for understanding their <em>in vivo</em> functions. Therefore, development of cross-species reactive anti-VEGF Nbs for immunotherapy of lung cancer was the main aim of the current study.<br /> <strong><em>Materials and Methods: </em></strong>Here we developed NBs from <em>Camelus </em><em>dromedarius</em> library with high specificity and binding affinity to both human and mouse VEGF. <em>In</em> <em>vitro</em> and <em>In vivo</em> function of developed NB was evaluated on human endothelial cells and lung epithelial tumor cells (TC-1).<br /> <strong><em>Results:</em></strong> A nanobody showed the highest affinity to human and mouse VEGF and potently inhibited VEGF in the ELISA experiment. Anti-VEGF NBs significantly inhibited <em>in vitro</em> human endothelial cell migration through blockade of VEGF (<em>P</em>=0.045). Anti-VEGF NBs also significantly inhibited <em>in vivo</em> TC-1 growth in a dose-dependent manner (<em>P</em>=0.001) and resulted in higher survival rate in the nanobody treated group<br /> <strong><em>Conclusion:</em></strong> These findings demonstrate the potential of anti-VEGF NBsin tumor growth inhibition and are promising as novel cancer therapeutic candidate.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Synergism effects of pioglitazone and Urtica dioica extract in streptozotocin-induced nephropathy via attenuation of oxidative stress497502867310.22038/ijbms.2017.8673ENMohammad ShokrzadehPharmaceutical Science Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran0000-0000-0000-0000Sara Sadat-hosseiniDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranMarjan FallahDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranFatemeh ShakiPharmaceutical Science Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran0000-0002-5440-3513Journal Article20170502<strong><em>Objective(s)</em></strong>: Hyperglycemia promotes oxidative stress that plays a crucial role in the pathogenesis of Diabetic nephropathy (DN). In this study, we investigated the synergism effects of hydroalcoholic extract of <em>Urtica dioica</em> and pioglitazone (PIO) on the prevention of DN in streptozotocin induced-diabetic mice.<br /> <strong><em>Materials and Methods</em></strong><strong><em>: </em></strong>Forty-two mice were divided into six groups as follows: non-diabetic control group, DMSO group (as solvent), diabetic group and four treatment groups which received <em>U. dioica</em>, pioglitazone, <em>U. dioica </em>plus pioglitazone and vitE. Diabetes was induced by a single dose of streptozotocin (STZ) (200 mg/kg body wt, IP) diluted in citrate buffer (pH= 4.6). After 4 weeks treatment, all animals were anaesthetized and blood was collected for serum urea and creatinine levels assessment in plasma and kidney tissue were excised for evaluation of oxidative stress markers.<br /> <strong><em>Results:</em></strong> Treatment with <em>U. dioica </em>significantly inhibited increase in serum urea and creatinine in plasma that were observed in diabetic mice. Furthermore, the elevated level of oxidative stress markers (glutathione oxidation, lipid peroxidation (LPO), protein carbonyl) in renal supernatant of diabetic mice was inhibited by <em>U. dioica</em> treatment. Interestingly, <em>U. dioica</em> promoted beneficial effects of PIO in reducing STZ-induced hyperglycemia, renal damage and oxidative stress markers.<br /> <strong><em>Conclusion:</em></strong> Our findings showed that PIO plus <em>U. dioica</em> have synergism protective effects against STZ-induced nephropathy that can be a candidate as a therapeutic approach in order to treatment of DN.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberis vulgaris for cardiovascular disorders: a scoping literature review503510867410.22038/ijbms.2017.8674ENAbdelrahman AbushoukFaculty of Medicine, Ain Shams University, Cairo, EgyptNovaMed Medical Research Association, Cairo, Egypt0000-0003-1399-6487Amr Muhammad Abdo SalemFaculty of Medicine, Ain Shams University, Cairo, EgyptNovaMed Medical Research Association, Cairo, EgyptMohamed MAbdel-DaimPharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, EgyptPharmacology Department, DY Patil Medical College, DY Patil University, Kolhapur, Maharashtra, IndiaJournal Article20170502Cardiovascular disorders are the leading cause of mortality worldwide. <em>Berberis vulgaris</em> (<em>B. vulgaris</em>) is a commonly used plant in traditional medicine. In recent studies, <em>B. vulgaris</em> showed antiarrhythmic, antihypertensive, anticholinergic, and cardioprotective effects. We reviewed the literature to explore the possible prophylactic and therapeutic roles of<em> B. vulgaris</em> in cardiovascular medicine. A computer literature search was conducted to identify all relevant studies that have investigated the role of <em>B. vulgaris</em> in prevention or treatment of cardiovascular diseases.We also searched the citations of the retrieved articles. Using a systematic approach, we conducted a scoping review that included a total of 37 articles. Twelve studies examined the antihypertensive effects of <em>B. vulgaris</em>, seven studies investigated its antiarrhythmic effects, while its inotropic and cardioprotective effects were evaluated in four and eight studies, respectively. <em>B. vulgaris</em> showed a beneficial effect in reducing blood pressure, enhancing cardiac contractility, and protection from reperfusion injury. However, the mechanisms of these effects are still under investigation. Moreover, it could modify major risk factors for cardiovascular disorders, such as oxidative stress, hyperglycemia, and hyperlipidemia. Further studies are needed to translate these findings into effective cardiovascular medications.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus511515867510.22038/ijbms.2017.8675ENSuhail Ahmed AlmaniDepartment of Medicine Liaquat University of Medical and Health Sciences Jamshoro, Sindh, PakistanIqbal Ahmed MemonDepartment of Medicine Liaquat University of Medical and Health Sciences Jamshoro, Sindh, PakistanTariq Zaffar ShaikhDepartment of Medicine Liaquat University of Medical and Health Sciences Jamshoro, Sindh, PakistanHaji Khan KhoharoFaculty of Medicine and Allied Medical Sciences Isra University, Hyderabad, Sindh, PakistanIkramuddin UjjanDepartment of Pathology Liaquat University of Medical and Health Sciences Jamshoro, Sindh, PakistanJournal Article20170502<strong><em>Objective(s)</em></strong>: Causality of occurrence of metformin-associated lactic acidosis (MALA) is a clinical problem. Currently, there is no drug available to prevent MALA. The present study was conducted to evaluate the protective effect of Berberine (BBR) against MALA in induced diabetic rat model.<br /> <strong><em>Materials and Methods: </em></strong>A sample of 75 healthy male Wistar rats was randomly selected according to inclusion and exclusion criteria. 75 male Wistar rats were randomly divided into a control and 4 experimental groups. Streptozotocin (STZ) in citrate buffer (pH 4.5) at a dose of 45 mg/kg was injected for induction of diabetes mellitus and rats achieving fasting blood glucose >250 mg/dl were included. Blood samples were collected 18 hr after the last dose of metformin and berberine. Ethical approval was taken before the study was conducted. Staistix 10.0 (USA) software was used for data analysis.<br /> <strong><em>Results:</em></strong> Berberine decreased MALA. Metformin, metformin + BBR 50 mg/kg bwt, and metformin + BBR 100 mg/kg bwt showed serum lactate as 1.87±0.4 mmol/lL, 1.62 ± 0.44 mmol/l and 1.47± 0.45 mmol/l, respectively (<em>P</em>=0.0001). Insulin resistance and liver enzymes were improved in BBR treated rats.<br /> <strong><em>Conclusion:</em></strong> The present study reports berberine protects against MALA in streptozocin-induced diabetes mellitus.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review516529867610.22038/ijbms.2017.8676ENSeyede Zohre Kamrani RadDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranMaryam RameshradDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranHossein HosseinzadehDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20170502<em>Berberis vulgaris</em> and berberine, its main component, traditionally have been used for treatment of various disorders. The pharmacological properties of them have been investigated using different <em>in vivo</em> and <em>in vitro</em> models. In spite of beneficial effects of <em>B. vulgaris</em> on different cell lines, there are documents have revealed negative impacts of it on animal and human. In this regards, the determination of its toxicity in a scientific view is necessary. In current report, we provide classified information about the toxicity of <em>B. vulgaris</em> and berberine in different conditions consist of acute, sub-acute, sub-chronic and chronic state. Besides, it discusses the cytotoxicity, genotoxicity, mutagenicity, and carcinogenicity of <em>B. vulgaris</em> and berberine as well as developmental toxicity and clinical studies. Data from the present study indicate that their toxicity is depending on the route and duration of administration. According to present study, they could induce GI upset and ulceration, immunotoxicity, phototoxicity, neurotoxicity, cardiotoxicity and jaundice in a dose dependent manner. They should be used with caution in pregnancy, neonatal and G6PD deficiency. Besides, consideration should be taken in co-administration of berberine with drugs that are metabolized with CYP enzymes due their inhibitory effects on these enzymes. Furthermore, they evoke cytotoxicity on both normal and cancer cell line which is time and concentration dependent.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Effects of berberine on the secretion of cytokines and expression of genes involved in cell cycle regulation in THP-1 monocytic cell line530537867710.22038/ijbms.2017.8677ENSaeed MohammadiStudent Research Committee and Department of Molecular Medicine, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran0000-0001-9895-8468Fakhri Sadat SeyedhoseiniInfectious Diseases Research Center and Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, IranJahanbakhsh AsadiDepartment of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, IranYaghoub YazdaniInfectious Diseases Research Center and Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, IranJournal Article20170502<strong><em>Objective(s)</em></strong>: Current acute myeloid leukemia (AML) therapeutic strategies have irreversible side-effects. Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand. AhR is a cytoplasmic receptor, which is involved in the regulation of cellular and immune responses. Here, we investigated the expression profile of genes involved in the cell cycle and different cytokines upon BBR-mediated AhR activation on AML THP-1 cell line.<br /> <strong><em>Materials and Methods: </em></strong>THP-1 cells and normal monocytes were treated with different concentrations of BBR (10 μM, 25 μM, 50 μM, and 100 μM) for 24 and 48 hr. The cell viability was measured by MTT assay. Real-time RT-PCR was conducted to evaluate the expression of AhR, cytochrome P450 1A1 (CYP1A1), interleukin 1 beta (IL1β), p21, p27, cyclin-dependent kinase 2 (CDK2) and p53. Cellular expression of AhR was also assessed using immunofluorescence method. ELISA was used to determine the level of IL-10 and IL-12 cytokines.<br /> <strong><em>Results:</em></strong> BBR inhibits the proliferation of THP-1 cells in a dose- and time-dependent manner with minimal toxicity on normal monocytes. Phorbol 12-myristate 13-acetate (PMA) treatment increased the cellular expression of AhR. The AhR target genes (CYP1A1, IL1β) were overexpressed upon BBR treatment. BBR downregulated Cdk2 and upregulated p21, p27 and p53 genes in THP-1 cells. IL-10 was significantly increased upon BBR treatment, while IL-12 was not significantly changed in all combinations.<br /> <strong><em>Conclusion:</em></strong> BBR could be introduced as an effective chemotherapeutic agent against AML by giving rise to the expression of CDK inhibitors and anti-inflammatory cytokines and downregulation of CDK2.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberis vulgaris and its constituent berberine as antidotes and protective agents against natural or chemical toxicities538551867810.22038/ijbms.2017.8678ENNooshin MohammadzadehSchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranSoghra MehriPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranHossein HosseinzadehPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20170502<em>Berberis vulgaris </em>L (<em>B. vulgaris</em>) and its main constituent berberine have been used in traditional medicine for a long time. This medicinal plant and berberine have many properties that have attracted the attention of researchers over the time. According to several studies, <em>B. vulgaris</em> and berberine exhibited anti-inflammatory, antioxidant, anticonvulsant, antidepressant, anti-Alzheimer, anti-cancer, anti-arrhythmic, antiviral, antibacterial and anti-diabetic effects in both <em>in vitro</em> and <em>in</em> <em>vivo</em> experiments. In regard to many reports on protective effects of <em>B. vulgaris</em> and berberine on natural and chemical toxins, in the current review article, the inhibitory effects of these compounds against natural, industrial, environmental and chemical toxicities with focus on cellular mechanism have been categorized. It has been mentioned that berberine could ameliorate toxicity of chemical toxins in brain, heart, kidney, liver and lung in part through antioxidant, anti-inflammatory, anti-apoptotic, modulation of mitogen-activated protein kinase (MAPK) and nuclear factor-ĸB (NF-ĸB) signaling pathways.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501The effects of ethanol extract of Berberis vulgaris fruit on histopathological changes and biochemical markers of the liver damage in diabetic rats552556868110.22038/ijbms.2017.8681ENMohammad Rahimi-MadisehMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran0000-0002-3108-4708Paridokht KarimianDepartment of Pathology, Shahrekord University of Medical Sciences, Shahrekord, IranMarzieh KafeshaniDepartment of Clinical Nutrition/Community Nutrition/Food Science & Technology, Food Security Research Center, School of Nutrition & Food Science, Isfahan, IranMahmoud Rafieian-KopaeiMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, IranJournal Article20170502<strong><em>Objective(s)</em></strong>: Various studies have shown that the diabetes is associated with liver failure. The objective of this study was determining the effects of <em>Berberis vulgaris</em> fruit on histopathological and biochemical markers of liver in diabetic rats.<br /> <strong><em>Materials and Methods: </em></strong>In this experimental study, 60 male Wistar rats weighing 200-250 g with free access to water and <em>ad libitum</em> were randomly divided to five twelve-membered groups including healthy control (group 1), diabetic control (group 2, this two groups received distilled water), treated diabetic positive control (group 3) using dose 150 mg/kg/day metformin, and two groups treated with doses 200 (group 4) and 600 (group 5) mg/kg/BW of <em>B. vulgaris</em> extracts via gavage feeding for 8 weeks. Diabetes mellitus was experimentally induced by one dose injection of alloxan 120 mg/kg. This pre-clinical study was performed on 120 mg/kg alloxan induced diabetic rats.<br /> <strong><em>Results:</em></strong> The hepatic steatosis status, liver cholestasis and fibrosis were not changed in group 4 and 5. Glycogen deposition changed mildly and polymorphonuclear neutrophils infiltration changed moderately at group 5. Liver hepatitis changed mildly and severely at group 3 as well as group 5, respectively. Glucose, serum glutamic-oxaloacetic transaminase, serum glutamic pyruvic transaminase, and alkaline phosphatase were lower in high dose group compared to other groups.<br /> <strong><em>Conclusion:</em></strong> Results suggested that <em>B. vulgaris</em> extract can decrease liver damage by influencing hepatic histopathological and biochemical markers in diabetic rats.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome557568868210.22038/ijbms.2017.8682ENJamshid TabeshpourDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, IranMohsen ImenshahidiDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranHossein HosseinzadehDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20170502Metabolic syndrome (MetS), characterized by a cluster of metabolic abnormalities including hypertension, obesity, type 2 diabetes mellitus (T2DM) and dyslipidemia, is a well-known cardiovascular risk factor (CVRF). Cardiovascular disease (CVD) represents a massive healthcare burden worldwide. In recent years, with regard to the adverse effects of synthetic drugs, increasing attention has been paid by researchers to herbal medicines for a variety of disorders such as CVD. A large body of literature supports different pharmacological actions of <em>Berberis vulgaris</em> (<em>B. vulgaris</em>) and its active component, berberine (BBR), such as antidiabetic, antiobesity, hypotensive and hypolipidemic properties that could be interesting in the management of MetS associated with high CVD risk. Numerous preclinical <em>in vitro</em> and <em>in vivo </em>studies support all these effects. In this review, we evaluated the most related original articles to discover the role of <em>B. vulgaris</em> on various constituents of MetS and CVRF comprising dyslipidemia, obesity, high blood pressure and high blood glucose.<br /> This review suggests a potential role of <em>B. vulgaris</em> and BBR in the managing of MetS; nevertheless more investigations, especially reliable clinical trials, need to be accomplished to evaluate their effectiveness.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberis vulgaris: specifications and traditional uses569587869010.22038/ijbms.2017.8690ENMohammad Rahimi-MadisehMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran0000-0002-3108-4708Zahra LorigoiniMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, IranHajar Zamani-gharaghoshiDepartment of Chemistry, Faculty of Sciences, Shahrekord University, Shahrekord, IranMahmoud Rafieian-kopaeiMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran0000-0002-1860-1141Journal Article20170503The medicinal plants from genus <em>Berberis </em>are particularly important in traditional medicine and the food basket of Iranians. Given various plants from genus <em>Berberis</em> and their economic, nutritional, and medicinal status in Iran, this study seeks to investigate the findings of recent studies on the phytochemical characteristics, specifications, and uses of <em>Berberis vulgaris</em>. In this review article, 350 articles were initially retrieved from reliable scientific databases using relevant search terms. Then, 230 articles were selected and 120 were excluded after a primary analysis. Finally, 98 articles related to the subject under study were meticulously examined and the required data were extracted and classified according to the research purposes. The findings were divided into eight separate sections: Introducing Berberidaceae family, different species of Berberis, pharmaceutical organs, <em>B. vulgaris</em> nutrition facts and minerals, the antioxidants and alkaloids compounds in fruit and other organs, action mechanisms of preventing and treating diseases, traditional uses of <em>B. vulgaris</em>, and its properties reported by recent studies. The results briefly indicate that <em>B. vulgaris </em>contains a large number of phytochemical materials including ascorbic acid, vitamin K, several triterpenoids, more than 10 phenolic compounds and more than 30 alkaloids. Therefore <em>B. vulgaris</em> may have anti-cancer, anti-inflammatory, antioxidant, antidiabetic, antibacterial, analgesic and anti-nociceptive and hepato-protective effects. Regarding the use of different organs of <em>B. vulgaris</em> in traditional medicine and their confirmed effects in the recent studies, it is possible to use different organs of <em>B. vulgaris</em>, especially fruit, to develop new drugs.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberine attenuates convulsing behavior and extracellular glutamate and aspartate changes in 4-aminopyridine treated rats588593875610.22038/ijbms.2017.8756ENHamid Reza SadeghniaNeurocognitive Research Center, Mashhad University of Medical Sciences, Mashhad, IranPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, IranAli Reza TajiPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, IranFatemeh ForouzanfarNeurocognitive Research Center, Mashhad University of Medical Sciences, Mashhad, IranHossein HosseinzadehPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20170517<strong><em>Objective(s)</em></strong>: K<sup>+ </sup>channel blocker 4-aminopyridine (4-AP) stimulates the release of glutamate from nerve terminals and induces seizures. Berberine as a potential herbal drug exerts several pharmacological actions on the central nervous system including anxiolytic, anticonvulsant, and neuroprotective properties. The present study aimed to investigate the effect of berberine on seizure onset and time course of the extracellular levels of excitatory amino acids (EAA), glutamate and aspartate, changes produced by 4-AP in rat hippocampus.<br /> <strong><em>Materials and Methods: </em></strong>The rats were given either saline or berberine (50, 100 and 200 mg/kg, IP) 40 min before administration of 4-AP (15 mg/kg, IP) and the onset of seizure was recorded. A group of rats also received diazepam (DZP, 15 mg/kg, IP) 20 min prior to 4-AP administration. Hippocampal extracellular levels of EAA were also measured using microdialysis assay. Analysis of the dialysate samples was performed by reversed-phase high performance liquid chromatography (HPLC) with precolumn derivatization with o-phthaldialdehyde and fluorescence detection.<br /> <strong><em>Results:</em></strong> Our findings suggest that berberine significantly delayed the seizure onset following 4-AP injection. There was a considerable increase in the extracellular glutamate and aspartate levels in 4-AP treated rats and 4-AP-evoked release of EAA was sharply reduced (about 4-5 fold especially at 20 min after 4-AP administration) in berberine treatment groups.<br /> <strong><em>Conclusion:</em></strong> The results of present study show that berberine attenuates 4-AP induced seizures by decreasing hippocampal aspartate and glutamate release in rats.Mashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-386620520170501Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells594603884710.22038/ijbms.2017.8847ENHamid Reza SadeghniaDivision of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, IranPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, IranMonireh KolangikhahPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, IranElham AsadpourAnesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, IranFatemeh ForouzanfarPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, IranHossein HosseinzadehPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20170606<strong><em>Objective(s)</em></strong>: Neurodegenerative diseases have been associated with glutamatergic dysfunction. Berberine, an isoquinoline alkaloid broadly present in different medicinal herbs, has been reported to have neuroprotective effect. In the present study, the effects of berberine against glutamate-induced oxidative damage and apoptosis were investigated.<br /> <strong><em>Materials and Methods: </em></strong>The cultured PC12 and N2a cells were pretreated (2 hr) with varying concentrations of berberine (50-1000 µM), followed by exposure to glutamate (10 mM) for 24 hr. The cells viability, intracellular reactive oxygen species (ROS), lipid peroxidation, glutathione (GSH) content, superoxide dismutase (SOD) activity, DNA fragmentation and the expressions of pro-apoptotic (cleaved caspase-3 and bax) and anti-apoptotic (bcl-2) proteins were then measured.<br /> <strong><em>Results:</em></strong> In both cell lines, pretreatment with berberine (especially at low concentrations) significantly decreased ROS generation, lipid peroxidation, and DNA fragmentation, while improving glutathione content and SOD activity in glutamate-injured cells. Moreover, berberine showed anti-apoptotic effects by reducing the glutamate-evoked caspase-3 and bax/bcl-2 overexpression.<br /> <strong><em>Conclusion:</em></strong> The results of present study suggest that berberine protects against glutamate-induced PC12 and N2a cells injury by decreasing oxidative stress and subsequently inhibiting apoptosis. This is relevant to berberine treatment in neurodegenerative disorders, such as dementia (Alzheimer’s disease), seizures, and stroke.